Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease?

Cancer

Volumn 121, Issue 6, 2015, Pages 830-835

  Price, Timothy J ^a   Beeke, Carol ^b   Ullah, Shahid ^c   Padbury, Robert ^b   Maddern, Guy ^d   Roder, David ^e   Townsend, Amanda R ^a   Moore, James ^f   Roy, Amitesh ^g   Tomita, Yoko ^a   Karapetis, Christos ^g  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

^d QUEEN ELIZABETH HOSPITAL   (Australia)

^e UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^f ROYAL ADELAIDE HOSPITAL   (Australia)

^g FLINDERS UNIVERSITY   (Australia)

Author keywords

Colorectal cancer; Primary site; Registry; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUSTRALIA; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER REGISTRY; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; LIVER METASTASIS; LIVER RESECTION; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; SEX DIFFERENCE; SURVIVAL TIME; TREATMENT OUTCOME; ADOLESCENT; COLORECTAL TUMOR; EPIDEMIOLOGY; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SOUTH AUSTRALIA; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84924106166     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29129     Document Type: Article

References (16)

1. Cancer in Australia: Actual incidence data from 1991 to 2009 and mortality data from 1991 to 2010 with projections to 2012. Asia Pac J Clin Oncol. 2013;9:199-213.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767.
3. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 1990; 113:779-788.
4. Araki K, Furuya Y, Kobayashi M, Matsuura K, Ogata T, Isozaki H. Comparison of mucosal microvasculature between the proximal and distal human colon. J Electron Microsc (Tokyo). 1996;45:202-206.
5. Arai T, Kino I. Morphometrical and cell kinetic studies of normal human colorectal mucosa. Comparison between the proximal and the distal large intestine. Acta Pathol Jpn. 1989;39:725-370.
6. Pocard M, Salmon RJ, Muleris M, et al. [Two colons-two cancers? Proximal or distal adenocarcinoma: arguments for a different carcinogenesis]. Bull Cancer. 1995;82:10-21.
7. Distler P, Holt PR. Are right-and left-sided colon neoplasms distinct tumors? Dig Dis. 1997;15:302-311.
8. Jess P, Hansen IO, Gamborg M, Jess T. A nationwide Danish cohort study challenging the categorisation into right-sided and leftsided colon cancer. BMJ Open. 2013;3.
9. Benedix F, Meyer F, Kube R, et al. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma. Pathol Res Pract. 2012;208:592-597.
10. Brule SY, Karapetis CS, O'Callaghan CJ, et al. Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): NCIC CTG CO.17. 2013 ASCO Annual Meeting. Chicago; Abstract 3528.
11. Boisen MK, Johansen JS, Dehlendorff C, et al. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Ann Oncol. 2013;24:2554-2559.
12. Neo EL, Beeke C, Price T, et al. South Australian clinical registry for metastatic colorectal cancer. ANZ J Surg. 2011;81:352-357.
13. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer. 2002;101:403-408.
14. Padman S, Padbury R, Beeke C, et al. Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy. Acta Oncol. 2013;52:1699-1706.
15. von Einem JC, Heinemann V, von Weikersthal LF, et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol. 2014;140:1607-1614.
16. Modest DP, Schulz C, von Weikersthal LF, et al. Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment). Anticancer Drugs. 2014;25:212-218.